Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review.
Servetto A, Salomone F, Di Costanzo F, Iuliano R, Marandino L, Napolitano F, Santaniello A, De Placido P, De Placido S, Di Maio M, Formisano L, Bianco R. Servetto A, et al. Among authors: di maio m, di costanzo f. Crit Rev Oncol Hematol. 2022 Apr;172:103649. doi: 10.1016/j.critrevonc.2022.103649. Epub 2022 Mar 5. Crit Rev Oncol Hematol. 2022. PMID: 35259486 Review.
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors.
Di Costanzo F, Napolitano F, Salomone F, Amato AR, Alberico G, Migliaccio F, Pecoraro G, Marra A, Crocetto F, Ruffo A, Scagliarini S, Rossetti S, Puglia L, Di Napoli M, Bianco R, Servetto A, Formisano L. Di Costanzo F, et al. Cancers (Basel). 2023 Dec 4;15(23):5703. doi: 10.3390/cancers15235703. Cancers (Basel). 2023. PMID: 38067406 Free PMC article.
Ribociclib in newly diagnosed hepatitis B infection: A case report.
Di Costanzo F, Carrano S, Iengo G, Cefaliello A, Cossiga V, Morisco F, Giuliano M, De Angelis C, Arpino G. Di Costanzo F, et al. Front Oncol. 2023 Jun 8;13:1184952. doi: 10.3389/fonc.2023.1184952. eCollection 2023. Front Oncol. 2023. PMID: 37361578 Free PMC article.
Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis.
Rizzo A, Schipilliti FM, Di Costanzo F, Acquafredda S, Arpino G, Puglisi F, Del Mastro L, Montemurro F, De Laurentiis M, Giuliano M. Rizzo A, et al. Among authors: di costanzo f. ESMO Open. 2023 Dec;8(6):102198. doi: 10.1016/j.esmoop.2023.102198. Epub 2023 Dec 14. ESMO Open. 2023. PMID: 38100933 Free PMC article.
190 results